Dendrite Announces Breakthrough Development Environment for Mobile Applications

Dendrite International, Inc. (NASDAQ: DRTE), a leading
provider of pharmaceutical industry solutions, today announced a
breakthrough, flexible sales and marketing application environment for
mobile devices. This environment, called Project Mobility, is designed
to address the increased need for portability, convenience and
personalization afforded by the latest mobile devices with smart phone
technology. Dendrite's mobile environment will be used to develop
applications designed to increase communication between every critical
member in the pharmaceutical chain, from home office to sales
representatives, as well as from prescriber to patients.
   With Dendrite's new application environment, companies will have
the same level of transparency as with today's sales force
effectiveness (SFE) applications, and will also benefit from the
freedom of a lightweight device, geo-centricity and real time
communication between home office and sales representative.
Longer-term, this breakthrough application environment will enable the
next generation of direct to patient health management marketing
programs.
   While Dendrite's first mobile application, jForceWireless(TM), was
launched in the second quarter of 2006 for China and other emerging
markets, the next applications will target the United States domestic
market. They will later be introduced in Europe and Australia.
Dendrite will develop all future applications residing in this
environment using Microsoft's Mobile PC platform. All of the
applications developed on this platform will be device-agnostic using
smart phone technology.
   "This environment is designed to enable a broader range of life
sciences companies to benefit from Dendrite's robust solutions and
deep domain knowledge," said John Bailye, Dendrite's chairman and
chief executive officer. "Smaller pharmaceutical or medical device
companies that previously couldn't afford Dendrite's solutions now
can; larger companies will have the opportunity to augment their
existing Dendrite architecture as companion products; and all
companies that need to tackle the common prescriber to patient
communication issues will have the means by which to open a dialog."
   The next application from this environment, an SFE solution for
small to medium sized pharmaceutical and medical device companies, is
currently being developed with feedback from certain prospective
customers. Dendrite currently anticipates roll-out in the fourth
quarter of 2006. Following this initial application, the company
expects to release several additional solutions in 2007 and beyond.
These solutions will be designed to work together to address issues
including patient adherence and physician marketing, among others.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.